Prosecution Insights
Prosecution Insights
34 pending office actions • 12 clients • 31 examiners • 25 art units • 0 of 34 (0%) have an AI response strategy ready • 37 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 34 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 34 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (3%) |
| §103 only | 17 (50%) |
| §102 only | 1 (3%) |
| §112 only | 8 (24%) |
| Double-patenting + other | 1 (3%) |
| No statute on record | 6 (18%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAMIREZ, DELIA M | 3 | 65.0% | +56.5% |
| VISHNYAKOVA, ELENA VLADIMIROVNA | 2 | 59.3% | +73.3% |
| KUCKLA, ANNA GRACE | 1 | 51.3% | +52.1% |
| GRAHAM, ANDREW D | 1 | 59.7% | +21.9% |
| WANG, XIAOBEI | 1 | 64.9% | +48.4% |
| ANDREWS, MICHAEL | 1 | 64.0% | +24.7% |
| PAGE, BRENT T | 1 | 82.5% | +10.7% |
| OGDEN JR, NECHOLUS | 1 | 69.8% | +23.7% |
| ALLEN, MICHAEL D | 1 | 32.6% | +48.7% |
| FEELY, MICHAEL J | 1 | 75.1% | +41.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921417 | METHOD OF DIAGNOSING A BIOLOGICAL ENTITY, AND DIAGNOSTIC DEVICE | ERICKSON, BENNETT S | 26d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18628213 | NANOPOROUS ALLOYS | WANG, XIAOBEI | 140d overdue |
| 18688206 | STATOR WITH PERMANENT PROTECTIVE BARRIER SEALING | ANDREWS, MICHAEL | 70d overdue |
| 18990537 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | VISHNYAKOVA, ELENA VLADIMIROVNA | 66d overdue |
| 18277904 | SURFACTANT COMPOSITIONS | OGDEN JR, NECHOLUS | 8d overdue |
| 18216135 | COMPOSITION AND METHOD | FEELY, MICHAEL J | 4d overdue |
| 16450852 | NOVEL CRISPR ENZYMES AND SYSTEMS | RAMIREZ, DELIA M | 9d |
| 16450825 | NOVEL CRISPR ENZYMES AND SYSTEMS | RAMIREZ, DELIA M | 14d |
| 19329060 | VERY LONG CHAIN FATTY ACIDS FOR TREATMENT AND ALLEVIATION OF DISEASES | KUCKLA, ANNA GRACE | 23d |
| Art Unit | Apps |
|---|---|
| 1652 | 4 |
| 1691 | 2 |
| 1671 | 2 |
| 1635 | 2 |
| 1672 | 2 |
| 1656 | 2 |
| 1681 | 2 |
| 1626 | 1 |
| 1742 | 1 |
| 1784 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19329060 | VERY LONG CHAIN FATTY ACIDS FOR TREATMENT AND ALLEVIATION OF DISEASES | Epax Norway AS | KUCKLA, ANNA GRACE | 1626 | §103 | Non-Final OA | 23d | Pending | Sep 15, 2025 |
| 18990537 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | The Brigham And Women'S Hospital, Inc. | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103 | Final Rejection | 66d overdue | Pending | Dec 20, 2024 |
| 18849107 | THREE DIMENSIONAL PRINTING PROCESS FLOW MANAGEMENT AND SUPPORT SYSTEMS | Azul 3D, Inc. | GRAHAM, ANDREW D | 1742 | §103 | Non-Final OA | 53d | Pending | Sep 20, 2024 |
| 18628213 | NANOPOROUS ALLOYS | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | WANG, XIAOBEI | 1784 | §103 | Non-Final OA | 140d overdue | Pending | Apr 05, 2024 |
| 18688206 | STATOR WITH PERMANENT PROTECTIVE BARRIER SEALING | Elaphe Propulsion Technologies, Ltd. | ANDREWS, MICHAEL | 2834 | §112 | Non-Final OA | 70d overdue | Pending | Feb 29, 2024 |
| 18430788 | MULTI-EFFECTOR CRISPR BASED DIAGNOSTIC SYSTEMS | President and Fellows of Harvard College | PAGE, BRENT T | 1663 | Other | Non-Final OA | 41d | Pending | Feb 02, 2024 |
| 18277904 | SURFACTANT COMPOSITIONS | Lankem Ltd. | OGDEN JR, NECHOLUS | 1761 | §102 | Non-Final OA | 8d overdue | Pending | Aug 18, 2023 |
| 18277612 | METHODS OF STRATIFYING AND TREATING CORONAVIRUS INFECTION | University of Mississippi Medical Center | ALLEN, MICHAEL D | 1671 | §103 | Non-Final OA | 53d | Pending | Aug 17, 2023 |
| 18216135 | COMPOSITION AND METHOD | Lankem Ltd. | FEELY, MICHAEL J | 1766 | §103 | Non-Final OA | 4d overdue | Pending | Jun 29, 2023 |
| 18334074 | TYPE VI CRISPR ORTHOLOGS AND SYSTEMS | President and Fellows of Harvard College | KONOPKA, CATHERINE ANNE | 1635 | Other | Non-Final OA | 9d | Pending | Jun 13, 2023 |
| 18032868 | REPROGRAMMABLE ISCB NUCLEASES AND USES THEREOF | Massachusetts Institute Of Technology | SU-TOBON, QIWEN NMN | 1636 | Other | Non-Final OA | 9d | Pending | Apr 20, 2023 |
| 18248199 | HELITRON MEDIATED GENETIC MODIFICATION | Massachusetts Institute Of Technology | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103 | Non-Final OA | 25d overdue | Pending | Apr 06, 2023 |
| 18026866 | CELL-FREE ANTIBODY ENGINEERING PLATFORM AND NEUTRALIZING ANTIBODIES FOR SARS-COV-2 | Massachusetts Institute Of Technology | BOESEN, AGNIESZKA | 1672 | §112 | Non-Final OA | 22d | Pending | Mar 17, 2023 |
| 17999364 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | The Brigham And Women'S Hospital, Inc. | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | Other | Final Rejection | 53d | Pending | Nov 18, 2022 |
| 17921417 | METHOD OF DIAGNOSING A BIOLOGICAL ENTITY, AND DIAGNOSTIC DEVICE | Oxford University Innovation Limited | ERICKSON, BENNETT S | 3683 | §101 | Final Rejection | 26d overdue | Pending | Oct 26, 2022 |
| 17916087 | SEQUENCING-BASED POPULATION SCALE SCREENING | Massachusetts Institute Of Technology | YAMASAKI, ROBERT J | 1657 | §103 | Final Rejection | 34d | Pending | Sep 30, 2022 |
| 17786168 | GENOME EDITING USING REVERSE TRANSCRIPTASE ENABLED AND FULLY ACTIVE CRISPR COMPLEXES | Massachusetts Institute Of Technology | LEE, JAE W | 1656 | §103 | Final Rejection | 33d | Pending | Jun 16, 2022 |
| 17707951 | ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS | Massachusetts Institute Of Technology | WEHBE, ANNE MARIE SABRINA | 1634 | §103 | Non-Final OA | 99d overdue | Pending | Mar 30, 2022 |
| 17764509 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | Massachusetts Institute Of Technology | CHESTNUT, BARRY A | 1672 | DPOther | Non-Final OA | 77d | Pending | Mar 28, 2022 |
| 17616621 | CRISPR SYSTEM HIGH THROUGHPUT DIAGNOSTIC SYSTEMS AND METHODS | The General Hospital Corporation | POHNERT, STEVEN C | 1683 | Other | Non-Final OA | 53d | Pending | Dec 03, 2021 |
| 17614602 | METHODS AND COMPOSITIONS FOR MODULATING IMMUNE RESPONSES | Massachusetts Institute Of Technology | PARKIN, JEFFREY S | 1671 | §112 | Final Rejection | 28d | Pending | Nov 29, 2021 |
| 17600799 | METHODS AND COMPOSITIONS FOR CELL THERAPY | The Brigham And Women'S Hospital, Inc. | JOHNSON, ALLISON MARIE | 1638 | §103 | Non-Final OA | 14d | Pending | Oct 01, 2021 |
| 17439063 | CRISPR EFFECTOR SYSTEM BASED MULTIPLEX DIAGNOSTICS | President and Fellows of Harvard College | SISSON, BRADLEY L | 1682 | §103 | Final Rejection | 29d | Pending | Sep 14, 2021 |
| 17294179 | CRISPR SYSTEM BASED DROPLET DIAGNOSTIC SYSTEMS AND METHODS | The General Hospital Corporation | GIAMMONA, FRANCESCA FILIPPA | 1681 | §103 | Non-Final OA | 3d overdue | Pending | May 14, 2021 |
| 17273999 | NUCLEIC ACID ASSEMBLIES FOR USE IN TARGETED DELIVERY | Massachusetts Institute Of Technology | SMALL, KATHERINE R | 1633 | §103 | Final Rejection | 20d | Pending | Mar 05, 2021 |
| 17254886 | CRISPR DOUBLE NICKASE BASED AMPLIFICATION COMPOSITIONS, SYSTEMS, AND METHODS | President and Fellows of Harvard College | GREENE, CAROLYN LEE | 1681 | §112 | Non-Final OA | 30d overdue | Pending | Dec 22, 2020 |
| 17085937 | BACTERIAL DEFENSE SYSTEMS AND METHODS OF IDENTIFYING THEREOF | Massachusetts Institute Of Technology | RYAN, DOUGLAS CHARLES | 1635 | §112 | Non-Final OA | 3d overdue | Pending | Oct 30, 2020 |
| 16936197 | FUNCTIONALIZED SOLID SUPPORT | Massachusetts Institute Of Technology | BUNKER, AMY M | 1684 | §103 | Non-Final OA | 9d overdue | Pending | Jul 22, 2020 |
| 16954032 | CAS12A SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED RNA BASE EDITING | Massachusetts Institute Of Technology | HUTSON, RICHARD G | 1652 | Other | Non-Final OA | 20d | Pending | Jun 15, 2020 |
| 16772269 | CAS12B SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED RNA BASE EDITING | Massachusetts Institute Of Technology | RAMIREZ, DELIA M | 1652 | §112 | Non-Final OA | 70d | Pending | Jun 12, 2020 |
| 16756134 | SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING | President and Fellows of Harvard College | STEADMAN, DAVID J | 1656 | §103 | Non-Final OA | 3d overdue | Pending | Apr 15, 2020 |
| 16632332 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES | The General Hospital Corporation | STAVROU, CONSTANTINA E | 1632 | §103 | Final Rejection | 29d | Pending | Jan 17, 2020 |
| 16450852 | NOVEL CRISPR ENZYMES AND SYSTEMS | The United States Department of Health and Human Services | RAMIREZ, DELIA M | 1652 | §112 | Final Rejection | 9d | Pending | Jun 24, 2019 |
| 16450825 | NOVEL CRISPR ENZYMES AND SYSTEMS | The United States Department of Health and Human Services | RAMIREZ, DELIA M | 1652 | §112 | Final Rejection | 14d | Pending | Jun 24, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial